A lbumin is an important functional protein in the blood for maintaining normal permeability of the microvessel wall, inhibiting platelet aggregation, and reducing blood viscosity. 1-3 Serum albumin levels are inversely associated with myocardial infarction, atrial fibrillation, cardiovascular diseases, and death. 4-7 There has been increasing interest in the association between serum albumin levels and stroke in recent years. Several studies have suggested an inverse association between serum albumin concentrations and stroke risk. 8, 9 The underlying pathophysiology, however, remains unclear. 10 Ischemic stroke is a syndrome with heterogeneous causes, including cardiac embolism, large artery atherosclerosis, and small vessel diseases. 11 There is sparse data on whether the relationship between serum albumin and stroke risk varies by ischemic stroke subtype. To elucidate the mechanisms of effect of serum albumin on incidence of stroke, we investigated whether the association between serum albumin levels varied by ischemic stroke etiologies in a large, populationbased, multiethnic, prospective, cohort study.
Serum Albumin Levels
Baseline levels of serum albumin were assayed in all the participants by commercially available immunonephelometric procedures (Beckman Instruments, Brea, CA). 16 In 943 participants who participated in a MRI substudy, follow-up serum albumin levels were available.
Follow-Up
NOMAS participants are followed annually by telephonic interviews with an average annual contact rate of 99%. A positive screen for any potential cardiac or neurological event was followed up by an in-person assessment to determine whether a vascular event occurred. All admissions and discharges to New York-Presbyterian Hospital were prospectively screened to detect hospitalizations and outcomes that may not have been captured by telephonic interviews. Incident stroke was verified and classified by ≥2 study neurologists as described in previous reports. 17 Causes of death were determined from death certificates, medical records of hospitalizations, family interviews, and primary care physicians.
Stroke Classifications
Participants with ischemic stroke underwent a thorough review of medical history, neurological examinations, and any diagnostic evaluations (CT, MRI, MR angiography, carotid Doppler, transcranial Doppler, ECG, transesophageal or transthoracic echocardiogram, Holter monitoring, and conventional catheter angiography). At least 2 NOMAS neurologists classified each stroke case according to modified TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria into infarction due to large vessel atherosclerosis, cardioembolism, small vessel diseases, cryptogenic stroke, and stroke from other unusual causes using the best available information. The classification of ischemic subtypes is described in detail elsewhere. 18, 19 Disagreements were adjudicated by one of the principal investigators (R.L.S. or M.S.V.E.).
Data Analyses
The association of baseline serum albumin levels with other covariates was examined using the F-test and general linear regression models with adjustment for age. If the variables showed an aged-adjusted association with albumin level at a P value <0.1, we included them as covariates in the multivariable analysis. For the association analysis, time (years) at risk for a stroke was computed from the date of enrollment to the occurrence of incident event, death, loss to follow-up, or the most recent follow-up date as of October 2012, whichever came first. For the risk of overall or ischemic stroke, and ischemic stroke subtypes, albumin levels were analyzed as a continuous variable as well as a categorical variable defined according to tertiles of the distribution of baseline serum albumin levels: 2.7 to 4.2, 4.3 to 4.5, and 4.6 to 5.5 g/dL. We used tertiles as cutoffs because they were close to the 3 cutoffs used in a previous large, nationwide, population-based study, in which serum albumin levels <4.2 g/dL were associated with increased overall or nonhemorrhagic stroke risk, but no significant difference was found for levels >4.2 g/dL. 8 Cox proportional hazard models were used to estimate the multivariable-adjusted hazard ratio (HR) and 95% confidence interval (CI), after adjusting for age, sex, race-ethnicity (model 1), and additionally adjusting for body mass index, moderate alcohol drinking, diabetes mellitus, hypercholesterolemia, WBC count, estimated glomerular filtration rate, and history of atrial fibrillation (model 2). No significant interaction between baseline albumin level and time at risk was found for any event risk, suggesting no appreciable violations of proportional hazard assumptions. Weighted sums-of-squares Q-statistics were computed to test for heterogeneity in effect sizes of albumin levels across ischemic stroke subtypes. All data analyses were performed with SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC).
Results
Baseline characteristics of the study population and their relation to serum albumin levels are shown in Table 1 . The mean serum albumin level was 4.42±0.33g/dL among 2986 participants (mean age, 69±10 years; 62.8% women; 21.5% non-Hispanic white; 25.3% non-Hispanic black; 53.2% Hispanic). Among 943 participants with baseline and follow-up albumin levels available, median change in serum albumin levels (mean follow-up time of 8 years; range, 2-14 years) was 0.1 g/dL (interquartile range, 0.1-0.3 g/dL; Table I in the onlineonly Data Supplement). After adjusting for age, lower serum albumin levels were associated with female sex, non-Hispanic black race, higher body mass index, absence of hypercholesterolemia, diabetes mellitus, no moderate alcohol drinking, low (<4000/mm 3 ) or high (>10 000/mm 3 ) WBC counts, and low estimated glomerular filtration rate (<45 mL/min). There was no significant difference in baseline albumin levels by high school education, leisure time physical activity, hypertension, or total caloric intake.
During a median follow-up of 12 years, there were 329 incident strokes (271 ischemic). The incidence rate was 8.3 per 1000 person-years for ischemic stroke, including 2.0 for small vessel, 2.8 for cardioembolic stroke, 1.7 for cryptogenic stroke, and 1.1 for large vessel stroke ( Table 2 ). The analysis of baseline albumin levels as a continuous variable (model 2) showed a 88% (95% CI, 1.31-2.69) increase in all stroke risk, 85% (95% CI, 1.24-2.75) increase in ischemic stroke risk, 148% (95% CI, 1.26-4.90) increase in cardiac embolism risk, and 199% (95% CI, 1.29-6.94) increase in cryptogenic stroke risk for 1 g/dL decrease (Figure [A] ; Table II in the online-only Data Supplement). After adjusting for both sociodemographics and vascular risk factors (model 2), participants with serum albumin levels of 2.7 to 4.2 g/dL (the lowest tertile of the sample) had an increased risk of all stroke (HR, 1.76; 95% CI, 1.32-2.35), ischemic stroke (HR, 1.67; 95% CI, 1.21-2.29), cardioembolic stroke (HR, 1.92; 95% CI, 1.10-3.34), and cryptogenic stroke (HR, 2.59; 95% CI, 1.21-5.53) compared with those with levels of 4.6 to 5.5 g/dL (the top tertile of the sample as a reference; Figure [B] ). For cardioembolic stroke, HR increased to 1.99 after excluding cases with minor cardiac sources (n=18). Low albumin levels were not significantly associated with large vessel or lacunar stroke in continuous and categorical analyses ( Table II in the online-only Data Supplement). Participants with serum albumin levels of 4.3 to 4.5 g/dL (middle tertile of the sample) did not show a significantly increased risk for any stroke events, compared with those with reference serum albumin levels (4.6-5.5 g/dL). The Figure shows that there was a differential effect of low albumin level on ischemic stroke risk by subtype, and the association with ischemic stroke was mainly driven by the association with cardioembolic and cryptogenic stroke. Our exploratory analysis also showed that participants with low serum albumin levels of 2.7 to 4.2 g/dL had an increased risk (HR, 1.38; 95% CI, 0.98-1.96) of myocardial infarction compared with those with serum albumin levels of 4.6 to 5.5 g/dL ( Table III in 
Discussion
Low serum albumin levels were associated with an increased risk of all stroke and ischemic stroke in this multiethnic prospective cohort study. For ischemic stroke, this effect was mainly present for cardioembolic and cryptogenic stroke, but not for large vessel or small vessel disease. The differential effect of serum albumin levels on risk of ischemic stroke subtypes may suggest a relationship to the potential underlying mechanism of cerebral infarction.
Cardioembolic stroke is caused by a variety of heart diseases, but occurs most commonly in patients with atrial fibrillation, followed by ventricular thrombus due to myocardial infarction, structural heart defects or tumors, and valvular heart disease. 20 There is solid evidence that serum albumin levels are inversely related to heart diseases. In the Copenhagen City Heart Study among 8870 women and men free of cardiovascular disease, albumin levels were inversely associated with risk of atrial fibrillation among women. 5 In the Framingham offspring study, during 21.9 years of mean follow-up in 5124 subjects, lower serum albumin was associated with an increased risk of myocardial infarction in both sexes. 4 Low serum albumin levels were also associated with increased risk for heart failure in the elderly persons, independent of inflammation and incident coronary events. 21 Such relationships between serum albumin and heart diseases may account for our results. Participants with low serum albumin levels may be more likely to have cardiac disorders and, therefore, stroke caused by cardioembolism. In our cohort, the higher risk of myocardial infarction in participants with low serum albumin supports this hypothesis. Cryptogenic stroke has heterogeneous causes. Some suggested that these infarcts may represent emboli from an unrecognized source. 22, 23 Patent foramen ovale-related paradoxical emboli may account for a portion of this patient group. 22 In addition, cardiogenic embolism due to undetected paroxysmal atrial fibrillation is also likely responsible for a portion of cryptogenic ischemic strokes. 24, 25 In a 3-year, prospective, multicenter registry using 30-day outpatient cardiac monitoring, paroxysmal atrial fibrillation was detected in 29 of 239 patients (12%) with cryptogenic stroke. 25 Our study was not designed to include routine and prolonged outpatient cardiac monitoring to detect paroxysmal atrial fibrillation.
Interestingly, serum albumin levels were inversely related to cryptogenic stroke, similar to the cardioembolism group in our study. This raises a possibility that low serum albumin may be viewed as a potential biomarker of cardiac embolism in cryptogenic stroke.
Comparatively, there is controversy about the relationship between serum albumin levels and extracranial atherosclerosis. In a B-mode ultrasound study of carotid plaques and intimamedia thickness among white subjects from 592 randomly ascertained families (2072 subjects) in the National Heart, Lung, and Blood Institute Family Heart Study, 26 lower serum albumin levels were not associated with an increased risk of prevalent carotid atherosclerosis in either men or women. 26 In the Atherosclerosis Risk in Communities (ARIC) study, there was also no association between albumin and carotid intimamedia thickness after adjustment for traditional risk factors. 27 However, in a cross-sectional study of 8143 Japanese subjects who underwent general health screening tests, higher serum albumin levels were inversely associated with the prevalence of early carotid atherosclerosis. 28 The relationships between serum albumin levels and advanced atherosclerosis (>50% extracranial or intracranial stenosis) have been poorly studied. In our study, serum albumin levels were not significantly associated with large vessel atherosclerotic stroke. The results should be interpreted with caution, however, because of the low overall incidence of large vessel atherosclerotic stroke in our study. Only 35 of 271 strokes were due to large vessel disease, and therefore, we may have had insufficient power to detect an effect (Table 2 ). Nevertheless, our study suggested a lack of association between serum albumin levels and large vessel stroke. Further investigations with larger samples are required.
Little is known about the relationship between serum albumin levels and lacunar stroke or cryptogenic stroke. It has been hypothesized that some lacunar strokes can be caused by blood-brain barrier derangement with leakage of serum albumin and other toxins. 29 The cerebrospinal fluid/plasma albumin ratio, which was not available in this study, may be helpful for addressing this issue. 29 Our results, however, showed no association between serum albumin levels and lacunar stroke.
In most previous studies, only baseline serum albumin levels were used for analysis. Because albumin is also an index of nutrition and systemic inflammation, one may argue that individual serum albumin levels may change over time. NOMAS is an ongoing cohort study, which provides an opportunity for longitudinal assessment of serum biomarkers. Among 943 patients who had baseline and follow-up serum albumin assessments available, albumin levels were fairly stable during a mean of 8 years of follow-up, with ≈2% relative reduction in albumin levels. Our results are consistent with a longitudinal study in 639 patients aged ≥50 years where average serum albumin level was slightly decreased during a 6-year period, from 4.5 to 4.4 g/dL. 30 Taken together, these observations suggest that baseline serum albumin levels may be reasonably stable and valuable for predicting future risk of stroke. The underlying mechanisms for the association between low serum albumin levels and heart diseases remain unclear. Low level of serum albumin may be a marker of chronic systemic inflammation, whereas in physiological concentrations, serum albumin may act as an anti-inflammation protein and antioxidant, which can protect the heart and coronary arteries from damage. 31, 32 Our study has several limitations. First, albumin is a blood protein related to nutrition status and inflammation, 33 which we did not systematically investigate. There was no significant difference in baseline albumin levels by total caloric intake. However, body mass index and WBC count, markers of nutrition and inflammation, respectively, were also evaluated at baseline and demonstrated some differences. We adjusted our models for possible effect modification by these 2 factors and showed that the associations with albumin remained significant. This does not, however, exclude the possibility of residual confounding. Second, the relatively small sample size of ischemic strokes due to large vessel atherosclerosis prevented further analysis of intracranial and extracranial atherosclerosis, which may have different pathophysiology. In addition, the proportion of stroke subtypes in our study cohort differs from those reported in other studies, especially in comparison to hospital stroke registries. The differences are primarily because of study designs (community-based versus hospitalbased, prospective versus case-control), but also because of varying sample sizes and population heterogeneity from different race-ethnic origins. Caution may be needed in generalizing our findings to other population.
In conclusion, our study shows that low serum albumin levels are independently associated with ischemic stroke, in particular cardioembolic and cryptogenic ischemic strokes. Given the existing evidence of the link between low serum albumin and cardiac conditions, our results suggest some shared pathophysiological relationships between low serum albumin levels, cardiac embolism, and cryptogenic infarctions. 
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